Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis
Go back to Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis| Management Of Environmental Solutions & Technology (NASDAQ: MESO) | Delayed: 14.33 -0.05 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.38 | 52 Week High | $10.89 | |||
| Open | $14.42 | 52 Week Low | $3.50 | |||
| Day High | $14.49 | P/E | N/A | |||
| Day Low | $14.25 | EPS | $0.00 | |||
| Volume | 107,126 | |||||
| MESABI TRUST (NYSE: MSB) | Delayed: 25.78 +0.19 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.59 | 52 Week High | $11.74 | |||
| Open | $25.50 | 52 Week Low | $3.00 | |||
| Day High | $25.89 | P/E | 16.32 | |||
| Day Low | $25.38 | EPS | $1.58 | |||
| Volume | 16,452 | |||||
